Physician profile
Stephen Wehibe
NPI 1124015466
$206.25
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $13.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $46.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $26.03 | 2019 | |
| Genentech USA, INC. | $22.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.60 | 2019 | |
| Astellas Pharma US INC | $18.10 | 2019 | |
| Lilly USA, LLC | $15.28 | 2019 | |
| Amgen INC. | $14.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Wehibe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.